User menu

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Bibliographic reference Van Den Neste, Eric ; Schmitz, N ; Mounier, N ; Gill, D ; Linch, D ; et. al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.. In: Bone Marrow Transplantation, Vol. 51, no. 1, p. 51-57 (2015)
Permanent URL http://hdl.handle.net/2078.1/183427
  1. Philip Thierry, Guglielmi Cesare, Hagenbeek Anton, Somers Renier, Van Der Lelie Hans, Bron Dominique, Sonneveld Pieter, Gisselbrecht Christian, Cahn Jean-Yves, Harousseau Jean-Luc, Coiffier Bertrand, Biron Pierre, Mandelli Franco, Chauvin Franck, Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma, 10.1056/nejm199512073332305
  2. Gisselbrecht C, Hematology Am Soc Hematol Educ Program, 2012, 410 (2012)
  3. Vellenga E., van Putten W. L. J., van 't Veer M. B., Zijlstra J. M., Fibbe W. E., van Oers M. H. J., Verdonck L. F., Wijermans P. W., van Imhoff G. W., Lugtenburg P. J., Huijgens P. C., Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial, 10.1182/blood-2007-08-108415
  4. Karlin L, Onco Targets Ther, 6, 289 (2013)
  5. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., Lefort S., Marit G., Macro M., Sebban C., Belhadj K., Bordessoule D., Ferme C., Tilly H., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte, 10.1182/blood-2010-03-276246
  6. Gunnellini M, Adv Hematol, 2012, 195484 (2012)
  7. Gisselbrecht Christian, Glass Bertram, Mounier Nicolas, Singh Gill Devinder, Linch David C., Trneny Marek, Bosly Andre, Ketterer Nicolas, Shpilberg Ofer, Hagberg Hans, Ma David, Brière Josette, Moskowitz Craig H., Schmitz Norbert, Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era, 10.1200/jco.2010.28.1618
  8. Gisselbrecht Christian, Schmitz Norbert, Mounier Nicolas, Singh Gill Devinder, Linch David C., Trneny Marek, Bosly Andre, Milpied Noel J., Radford John, Ketterer Nicolas, Shpilberg Ofer, Dührsen Ulrich, Hagberg Hans, Ma David D., Viardot Andreas, Lowenthal Ray, Brière Josette, Salles Gilles, Moskowitz Craig H., Glass Bertram, Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma, 10.1200/jco.2012.41.9416
  9. Hamadani Mehdi, Hari Parameswaran N., Zhang Ying, Carreras Jeanette, Akpek Görgün, Aljurf Mahmoud D., Ayala Ernesto, Bachanova Veronika, Chen Andy I., Chen Yi-Bin, Costa Luciano J., Fenske Timothy S., Freytes César O., Ganguly Siddhartha, Hertzberg Mark S., Holmberg Leona A., Inwards David J., Kamble Rammurti T., Kanfer Edward J., Lazarus Hillard M., Marks David I., Nishihori Taiga, Olsson Richard, Reddy Nishitha M., Rizzieri David A., Savani Bipin N., Solh Melhem, Vose Julie M., Wirk Baldeep, Maloney David G., Smith Sonali M., Montoto Silvia, Saber Wael, Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation, 10.1016/j.bbmt.2014.06.036
  10. Mounier Nicolas, Canals Carmen, Gisselbrecht Christian, Cornelissen Jan, Foa Roberto, Conde Eulogio, Maertens John, Attal Michel, Rambaldi Alessandro, Crawley Charles, Luan Jian-Jian, Brune Mats, Wittnebel Sebastian, Cook Gordon, van Imhoff G.W., Pfreundschuh Michael, Sureda Anna, High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry, 10.1016/j.bbmt.2011.10.010
  11. Crump Michael, Kuruvilla John, Couban Stephen, MacDonald David A., Kukreti Vishal, Kouroukis C. Tom, Rubinger Morel, Buckstein Rena, Imrie Kevin R., Federico Massimo, Di Renzo Nicola, Howson-Jan Kang, Baetz Tara, Kaizer Leonard, Voralia Michael, Olney Harold J., Turner A. Robert, Sussman Jonathan, Hay Annette E., Djurfeldt Marina S., Meyer Ralph M., Chen Bingshu E., Shepherd Lois E., Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12, 10.1200/jco.2013.53.9593
  12. Van Den Neste E, Blood, 122, 764 (2013)
  13. Cheson Bruce D., Horning Sandra J., Coiffier Bertr, Shipp Margaret A., Fisher Richard I., Connors Joseph M., Lister T. Andrew, Vose Julie, Grillo-López Antonio, Hagenbeek Anton, Cabanillas Fernando, Klippensten Donald, Hiddemann Wolfgang, Castellino Ronald, Harris Nancy L., Armitage James O., Carter William, Hoppe Richard, Canellos George P., Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, 10.1200/jco.1999.17.4.1244
  14. Thieblemont Catherine, Briere Josette, Mounier Nicolas, Voelker Hans-Ullrich, Cuccuini Wendy, Hirchaud Edouard, Rosenwald Andreas, Jack Andrew, Sundstrom Christer, Cogliatti Sergio, Trougouboff Philippe, Boudova Ludmila, Ysebaert Loic, Soulier Jean, Chevalier Catherine, Bron Dominique, Schmitz Norbert, Gaulard Philippe, Houlgatte Remi, Gisselbrecht Christian, The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study, 10.1200/jco.2011.35.4423
  15. Hans C. P., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, 10.1182/blood-2003-05-1545
  16. Nagle Sarah J., Woo Kaitlin, Schuster Stephen J., Nasta Sunita D., Stadtmauer Edward, Mick Rosemarie, Svoboda Jakub, Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era, 10.1002/ajh.23524
  17. Hamadani Mehdi, Hari Parameswaran N., Zhang Ying, Carreras Jeanette, Akpek Görgün, Aljurf Mahmoud D., Ayala Ernesto, Bachanova Veronika, Chen Andy I., Chen Yi-Bin, Costa Luciano J., Fenske Timothy S., Freytes César O., Ganguly Siddhartha, Hertzberg Mark S., Holmberg Leona A., Inwards David J., Kamble Rammurti T., Kanfer Edward J., Lazarus Hillard M., Marks David I., Nishihori Taiga, Olsson Richard, Reddy Nishitha M., Rizzieri David A., Savani Bipin N., Solh Melhem, Vose Julie M., Wirk Baldeep, Maloney David G., Smith Sonali M., Montoto Silvia, Saber Wael, Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation, 10.1016/j.bbmt.2014.06.036
  18. Gisselbrecht Christian, Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?, 10.1016/j.bbmt.2014.08.021
  19. Glass Bertram, Hasenkamp Justin, Wulf Gerald, Dreger Peter, Pfreundschuh Michael, Gramatzki Martin, Silling Gerda, Wilhelm Christian, Zeis Matthias, Görlitz Anke, Pfeiffer Sebastian, Hilgers Reinhard, Truemper Lorenz, Schmitz Norbert, Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial, 10.1016/s1470-2045(14)70161-5
  20. Robinson S. P., Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, 10.1182/blood-2001-11-0107
  21. Chevallier P, Labopin M, Milpied N, Bilger K, Socié G, Yakoub-Agha I, Michallet M, Bulabois C-E, Maury S, Beguin Y, Bay J-O, Blaise D, Maillard N, Guillerm G, Daguindeau E, Raus N, Mohty M, Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), 10.1038/bmt.2013.186
  22. Hamadani Mehdi, Saber Wael, Ahn Kwang Woo, Carreras Jeanette, Cairo Mitchell S., Fenske Timothy S., Gale Robert Peter, Gibson John, Hale Gregory A., Hari Parameswaran N., Hsu Jack W., Inwards David J., Kamble Rammurti T., Klein Anderas, Maharaj Dipnarine, Marks David I., Rizzieri David A., Savani Bipin N., Schouten Harry C., Waller Edmund K., Wirk Baldeep, Laport Ginna G., Montoto Silvia, Maloney David G., Lazarus Hillard M., Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma, 10.1016/j.bbmt.2013.01.024
  23. van Kampen Roel J.W., Canals Carmen, Schouten Harry C., Nagler Arnon, Thomson Kirsty J., Vernant Jean-Paul, Buzyn Agnes, Boogaerts Marc A., Luan Jian-Jian, Maury Sébastien, Milpied Noel J., Jouet Jean-Pierre, Ossenkoppele Gert J., Sureda Anna, Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry, 10.1200/jco.2010.30.2596
  24. Elstrom Rebecca L., Martin Peter, Ostrow Katya, Barrientos Jacqueline, Chadburn Amy, Furman Richard, Ruan Jia, Shore Tsiporah, Schuster Michael, Cerchietti Leandro, Melnick Ari, Coleman Morton, Leonard John P., Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies, 10.3816/clml.2010.n.030
  25. Seshadri T., Stakiw J., Pintilie M., Keating A., Crump M., Kuruvilla J., Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy, 10.1179/102453308x343527
  26. Simpson Lijo, Ansell Stephen M., Colgan Joseph P., Habermann Thomas M., Inwards David J., Ristow Kay M., Johnston Patrick B., Markovic Svetomir N., Micallef Ivana N., Porrata Luis F., Witzig Thomas E., Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone, 10.1080/10428190701435259
  27. Ardeshna Kirit M., Kakouros Nicholaos, Qian Wendi, Powell Michael G., Saini Nishaat, D'Sa Shirley, Mackinnon Stephen, Hoskin Peter J., Goldstone Anthony H., Linch David C., Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens, 10.1111/j.1365-2141.2005.05603.x
  28. Valera A., Lopez-Guillermo A., Cardesa-Salzmann T., Climent F., Gonzalez-Barca E., Mercadal S., Espinosa I., Novelli S., Briones J., Mate J. L., Salamero O., Sancho J. M., Arenillas L., Serrano S., Erill N., Martinez D., Castillo P., Rovira J., Martinez A., Campo E., Colomo L., , MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, 10.3324/haematol.2013.086173
  29. Gisselbrecht Christian, Should We Replace Dexamethasone, Cytarabine, and Cisplatin for Relapsed Lymphoma?, 10.1200/jco.2014.56.6802
  30. Morschhauser Franck Andre, Cartron Guillaume, Thieblemont Catherine, Solal-Céligny Philippe, Haioun Corinne, Bouabdallah Reda, Feugier Pierre, Bouabdallah Krimo, Asikanius Elina, Lei Guiyuan, Wenger Michael, Wassner-Fritsch Elisabeth, Salles Gilles Andre, Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study, 10.1200/jco.2012.46.9585
  31. Matasar M. J., Czuczman M. S., Rodriguez M. A., Fennessy M., Shea T. C., Spitzer G., Lossos I. S., Kharfan-Dabaja M. A., Joyce R., Fayad L., Henkel K., Liao Q., Edvardsen K., Jewell R. C., Fecteau D., Singh R. P., Lisby S., Moskowitz C. H., Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma, 10.1182/blood-2012-12-472027
  32. Younes Anas, Thieblemont Catherine, Morschhauser Franck, Flinn Ian, Friedberg Jonathan W, Amorim Sandy, Hivert Benedicte, Westin Jason, Vermeulen Jessica, Bandyopadhyay Nibedita, de Vries Ronald, Balasubramanian Sriram, Hellemans Peter, Smit Johan W, Fourneau Nele, Oki Yasuhiro, Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study, 10.1016/s1470-2045(14)70311-0
  33. Mathews Griner Lesley A., Guha Rajarshi, Shinn Paul, Young Ryan M., Keller Jonathan M., Liu Dongbo, Goldlust Ian S., Yasgar Adam, McKnight Crystal, Boxer Matthew B., Duveau Damien Y., Jiang Jian-Kang, Michael Sam, Mierzwa Tim, Huang Wenwei, Walsh Martin J., Mott Bryan T., Patel Paresma, Leister William, Maloney David J., Leclair Christopher A., Rai Ganesha, Jadhav Ajit, Peyser Brian D., Austin Christopher P., Martin Scott E., Simeonov Anton, Ferrer Marc, Staudt Louis M., Thomas Craig J., High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells, 10.1073/pnas.1311846111